USD 1.41
(-0.28%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -6.64 Million USD | 63.62% |
2022 | -18.27 Million USD | -8.32% |
2021 | -16.86 Million USD | -27.98% |
2020 | -13.17 Million USD | -9.51% |
2019 | -12.03 Million USD | -59.24% |
2018 | -7.55 Million USD | -2.94% |
2017 | -7.34 Million USD | -87.0% |
2016 | -3.92 Million USD | -155.69% |
2015 | -1.53 Million USD | -104.82% |
2014 | -749.68 Thousand USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -715 Thousand USD | 49.67% |
2024 Q1 | -1.42 Million USD | -126.29% |
2023 Q2 | -1.49 Million USD | 11.16% |
2023 Q4 | 5.4 Million USD | 342.99% |
2023 FY | -6.64 Million USD | 63.62% |
2023 Q1 | -1.68 Million USD | 11.51% |
2023 Q3 | -2.22 Million USD | -48.66% |
2022 FY | -18.27 Million USD | -8.32% |
2022 Q1 | -4.75 Million USD | -99.62% |
2022 Q4 | -1.9 Million USD | 12.87% |
2022 Q3 | -2.18 Million USD | 67.79% |
2022 Q2 | -6.78 Million USD | -42.47% |
2021 FY | -16.86 Million USD | -27.98% |
2021 Q4 | -2.38 Million USD | 51.8% |
2021 Q1 | -4.49 Million USD | 4.28% |
2021 Q2 | -3.26 Million USD | 27.43% |
2021 Q3 | -4.94 Million USD | -51.49% |
2020 Q2 | -13.46 Million USD | -780.15% |
2020 FY | -13.17 Million USD | -9.51% |
2020 Q1 | 1.98 Million USD | 307.98% |
2020 Q4 | -4.7 Million USD | -69.55% |
2020 Q3 | -2.77 Million USD | 79.42% |
2019 Q3 | 2.07 Million USD | 117.03% |
2019 Q4 | -952 Thousand USD | -145.97% |
2019 FY | -12.03 Million USD | -59.24% |
2019 Q1 | -2.65 Million USD | -131.8% |
2019 Q2 | -12.15 Million USD | -358.07% |
2018 Q3 | -2.68 Million USD | -15.76% |
2018 Q2 | -2.32 Million USD | -66.08% |
2018 FY | -7.55 Million USD | -2.94% |
2018 Q4 | -1.14 Million USD | 57.44% |
2018 Q1 | -1.39 Million USD | -74.95% |
2017 Q3 | -1.51 Million USD | 36.9% |
2017 FY | -7.34 Million USD | -87.0% |
2017 Q1 | -2.62 Million USD | -30.74% |
2017 Q4 | -799.72 Thousand USD | 47.22% |
2017 Q2 | -2.4 Million USD | 8.55% |
2016 Q3 | -8352.00 USD | 21.71% |
2016 Q4 | -2 Million USD | -23947.27% |
2016 Q1 | -875.00 USD | 89.16% |
2016 Q2 | -10.66 Thousand USD | -1119.2% |
2016 FY | -3.92 Million USD | -155.69% |
2015 Q2 | 164.00 USD | 0.0% |
2015 Q4 | -8070.00 USD | -381.5% |
2015 Q3 | -1676.00 USD | -1121.95% |
2015 FY | -1.53 Million USD | -104.82% |
2014 FY | -749.68 Thousand USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 46.97 Million USD | 114.149% |
Aquestive Therapeutics, Inc. | -15.1 Million USD | 55.994% |
Collegium Pharmaceutical, Inc. | 166.96 Million USD | 103.98% |
Cosmos Health Inc. | -21.83 Million USD | 69.558% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 66.854% |
Esperion Therapeutics, Inc. | -155.56 Million USD | 95.728% |
Cronos Group Inc. | -81.37 Million USD | 91.833% |
Incannex Healthcare Limited | -30.04 Million USD | 77.878% |
Kala Pharmaceuticals, Inc. | -39.15 Million USD | 83.026% |
Lifecore Biomedical, Inc. | 9.33 Million USD | 171.223% |
Regencell Bioscience Holdings Limited | -4.73 Million USD | -40.303% |
Sunshine Biopharma, Inc. | -4.78 Million USD | -38.879% |
Sunshine Biopharma, Inc. | -4.78 Million USD | -38.879% |
SCYNEXIS, Inc. | 72.66 Million USD | 109.145% |
Safety Shot Inc | -12.18 Million USD | 45.455% |
Theratechnologies Inc. | -10.62 Million USD | 37.463% |
Alpha Teknova, Inc. | -35.56 Million USD | 81.313% |
Universe Pharmaceuticals INC | -3.52 Million USD | -88.438% |
Pacira BioSciences, Inc. | 87.67 Million USD | 107.58% |
Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -41.37% |
Dynavax Technologies Corporation | -37.02 Million USD | 82.052% |
Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 103.179% |
Radius Health, Inc. | -3.92 Million USD | -69.319% |
China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -164.223% |
Alvotech | -354.86 Million USD | 98.127% |
Intra-Cellular Therapies, Inc. | -159.38 Million USD | 95.83% |
SIGA Technologies, Inc. | 83.62 Million USD | 107.947% |
Shineco, Inc. | -17.06 Million USD | 61.058% |
Silver Spike Investment Corp. | 7.34 Million USD | 190.541% |
Journey Medical Corporation | -2.07 Million USD | -220.588% |
Petros Pharmaceuticals, Inc. | -13.61 Million USD | 51.196% |
Embecta Corp. | 221.5 Million USD | 103.0% |
Harrow Health, Inc. | 580 Thousand USD | 1245.825% |
Procaps Group, S.A. | 38.97 Million USD | 117.052% |
Biofrontera Inc. | -22.67 Million USD | 70.694% |
DURECT Corporation | -36.88 Million USD | 81.982% |
PainReform Ltd. | -9.58 Million USD | 30.658% |
Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -26.13% |
OptiNose, Inc. | -22.74 Million USD | 70.785% |
RedHill Biopharma Ltd. | 12.63 Million USD | 152.611% |
Organogenesis Holdings Inc. | 12.52 Million USD | 153.06% |
Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -7.003% |
ProPhase Labs, Inc. | -21.61 Million USD | 69.251% |
Phibro Animal Health Corporation | 53.31 Million USD | 112.465% |
Procaps Group S.A. | 52.32 Million USD | 112.701% |
TherapeuticsMD, Inc. | -8.52 Million USD | 22.025% |
Viatris Inc. | 766.2 Million USD | 100.867% |
Rockwell Medical, Inc. | -6.67 Million USD | 0.363% |
Aytu BioPharma, Inc. | -5.25 Million USD | -26.49% |
Tilray Brands, Inc. | -174.74 Million USD | 96.197% |
PetIQ, Inc. | 60.01 Million USD | 111.074% |
Talphera, Inc. | -16.88 Million USD | 60.65% |
Neurocrine Biosciences, Inc. | 250.9 Million USD | 102.649% |
Alimera Sciences, Inc. | -1.47 Million USD | -351.787% |
Assertio Holdings, Inc. | -243.53 Million USD | 97.271% |
Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -12.786% |
Avadel Pharmaceuticals plc | -137.84 Million USD | 95.179% |
Hempacco Co., Inc. | -8.81 Million USD | 24.585% |
Alvotech | -354.86 Million USD | 98.127% |
Lantheus Holdings, Inc. | 364.64 Million USD | 101.823% |
Kamada Ltd. | 10.06 Million USD | 166.035% |
Indivior PLC | -4 Million USD | -66.145% |
Evoke Pharma, Inc. | -7.43 Million USD | 10.565% |
Flora Growth Corp. | -50.35 Million USD | 86.802% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 66.854% |
Evolus, Inc. | -49.23 Million USD | 86.501% |
HUTCHMED (China) Limited | 18.37 Million USD | 136.168% |
Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 103.374% |
Akanda Corp. | -10.05 Million USD | 33.882% |